ArticleMovement disorders : official journal of the Movement Disorder Society2022
Serotonin Transporter Imaging in Multiple System Atrophy and Parkinson's Disease.
Article in Movement disorders : official journal of the Movement Disorder Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 28 citations in OpenAlex.
- The Role of Serotonergic System in Parkinson's Disease-Related Pain.Neuroscience bulletin · 2026Review
- Neuroimaging in multiple system atrophy: clinical implications and novel developments.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Serotonin Transporter Distribution in the Brainstem of Multiple-System Atrophy-Parkinsonian Type: Insights from Pathology andJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Regional homogeneity differences in resting-state fMRI between Parkinson's disease and multiple system atrophy-parkinsonian type.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- MRI-derived atrophy in multiple system atrophy aligns with mitochondrial and glial gene expression patterns.NPJ Parkinson's disease · 2025Article
- Use of the specific binding ratio distribution to characterise multiple system atrophy in advanced iodine-123-labelled N-(3-fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl) nortropane serotonin transporter imaging.Asia Oceania journal of nuclear medicine & biology · 2025Article
- Gut Microbiota and Its Metabolites: The Emerging Bridge Between Coronary Artery Disease and Anxiety and Depression?Aging and disease · 2024Review
- Positron Emission Tomography Imaging of Synaptic Dysfunction in Parkinson's Disease.Neuroscience bulletin · 2024Review
- Whole-brain dopamine transporter binding pattern predicts survival in multiple system atrophy.Translational neurodegeneration · 2024Article
- Serotonin transporter density in isolated rapid eye movement sleep behavioral disorder.Frontiers in sleep · 2024Article
- PET, SPECT, and MRI imaging for evaluation of Parkinson's disease.American journal of nuclear medicine and molecular imaging · 2024Review
- Outcome Measures for Disease-Modifying Trials in Parkinson's Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative.Journal of Parkinson's disease · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundBoth Parkinson's disease (PD) and multiple system atrophy (MSA) exhibit degeneration of brainstem serotoninergic nuclei, affecting multiple subcortical and cortical serotoninergic projections. In MSA, medullary serotoninergic neuron pathology is well documented, but serotonin system changes throughout the rest of the brain are less well characterized.
objectivesTo use serotonin transporter [
methodsWe performed serotonin transporter PET imaging in 18 patients with MSA, 23 patients with PD, and 16 healthy controls to explore differences in brainstem, subcortical, and cortical regions of interest.
resultsPatients with MSA showed lower serotonin transporter distribution volume ratios compared with patients with PD in the medulla, raphe pontis, ventral striatum, limbic cortex, and thalamic regions, but no differences in the dorsal striatal, ventral anterior cingulate, or total cortical regions. Controls showed greater cortical serotonin transporter binding compared with PD or MSA groups but lower serotonin transporter binding in the striatum and other relevant basal ganglia regions. There were no regional differences in binding between patients with MSA-parkinsonian subtype (n = 8) and patients with MSA-cerebellar subtype (n = 10). Serotonin transporter distribution volume ratios in multiple different regions of interest showed an inverse correlation with the severity of Movement Disorders Society Unified Parkinson's Disease Rating Scale motor score in patients with MSA but not patients with PD.
conclusionsBrainstem and some forebrain subcortical region serotoninergic deficits are more severe in MSA compared with PD and show an MSA-specific correlation with the severity of motor impairments. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.